Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A rapid method for determination of acetylation phenotype using dapsone.

Literature DB >> 6721993

A rapid method for determination of acetylation phenotype using dapsone.

Abstract

A rapid, simple one-stage protein precipitation method for the estimation of plasma dapsone (DDS) and monoacetyldapsone (MADDS) concentration by high-pressure liquid chromatography (h.p.l.c.) is described. Its performance in the assignment of acetylator phenotype was compared with a reference h.p.l.c. method utilising an extraction procedure and internal standard. The rapid h.p.l.c. technique combined with measurement of the plasma MADDS/DDS ratio is, in our opinion, the method of choice for the determination of the acetylator phenotype in population studies.

Entities: Chemical

Mesh：

Substances：
Dapsone
monoacetyldapsone

Year: 1984 PMID： 6721993 PMCID： PMC1463405 DOI： 10.1111/j.1365-2125.1984.tb02373.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

18 in total

1. Measuring agreement between two judges on the presence or absence of a trait.

Authors: J L Fleiss
Journal: Biometrics Date: 1975-09 Impact factor: 2.571

2. HUMAN ACETYLATION POLYMORPHISM.

Authors: D A EVANS; T A WHITE
Journal: J Lab Clin Med Date: 1964-03

Review 3. Disease and acetylation polymorphism.

Authors: P K Lunde; K Frislid; V Hansteen
Journal: Clin Pharmacokinet Date: 1977 May-Jun Impact factor: 6.447

4. A chromatographic-fluorometric procedure for the determination of nanogram quantities of antileprotic sulfones.

Authors: J F Murray; G R Gordon; J H Peters
Journal: J Lab Clin Med Date: 1971-09

5. An improved and simplified method of detecting the acetylator phenotype.

Authors: D A Evans
Journal: J Med Genet Date: 1969-12 Impact factor: 6.318

6. Acetylation pattern of different sulphonamides in rapid and slow isoniazid inactivators.

Authors: M J Mattila; H Tiitinen; E Alhava
Journal: Ann Med Exp Biol Fenn Date: 1969

7. The fluorometric measurement of 4,4'-diaminodiphenyl sulfone and its acetylated derivatives in plasma and urine.

Authors: J H Peters; G R Gordon; W T Colwell
Journal: J Lab Clin Med Date: 1970-08

8. The polymorphic acetylation of dapsone in man.

Authors: R Gelber; J H Peters; G R Gordon; A J Glazko; L Levy
Journal: Clin Pharmacol Ther Date: 1971 Mar-Apr Impact factor: 6.875

9. Polymorphic acetylation procainamide in man.

Authors: M M Reidenberg; D E Drayer; M Levy; H Warner
Journal: Clin Pharmacol Ther Date: 1975-06 Impact factor: 6.875

10. Absorption, metabolism and excretion of di(rho-aminophenyl) sulphone (dapsone) and di(rho-aminophenyl) sulphoxide in man.

Authors: G A Ellard
Journal: Br J Pharmacol Chemother Date: 1966-01

14 in total

A rapid method for determination of acetylation phenotype using dapsone.

1. Measuring agreement between two judges on the presence or absence of a trait.

2. HUMAN ACETYLATION POLYMORPHISM.

Review 3. Disease and acetylation polymorphism.

4. A chromatographic-fluorometric procedure for the determination of nanogram quantities of antileprotic sulfones.

5. An improved and simplified method of detecting the acetylator phenotype.

6. Acetylation pattern of different sulphonamides in rapid and slow isoniazid inactivators.

7. The fluorometric measurement of 4,4'-diaminodiphenyl sulfone and its acetylated derivatives in plasma and urine.

8. The polymorphic acetylation of dapsone in man.

9. Polymorphic acetylation procainamide in man.

10. Absorption, metabolism and excretion of di(rho-aminophenyl) sulphone (dapsone) and di(rho-aminophenyl) sulphoxide in man.

1. Effect of cancer chemotherapy on dapsone N-acetylation in man.

2. The pharmacokinetics of dapsone after oral administration to healthy volunteers.

3. Influence of age, sex and body weight on the dapsone acetylation phenotype.

4. Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients.

Review 5. Clinical pharmacokinetics of dapsone.

6. N-acetylation phenotyping with dapsone in a mainland Chinese population.

7. Acetylation and oxidation phenotypes in malignant lymphoma.

8. N-acetylation phenotyping using dapsone in a Jordanian population.

Review 9. Clinical pharmacokinetic considerations in the elderly. An update.

10. Pharmacokinetics of dapsone in human immunodeficiency virus-infected children.